The Milan Cell and Gene Center of Excellence at AGC Biologics will produce LVV material for Treg cell therapy candidates.

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

HCW Biologics Inc. (the "Company” or "HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

AGC Biologics has partnered with Quell Therapeutics to support the development of multiple Treg cell therapy drug candidates.

Creative Biolabs upgrades its therapeutic antibody and protein development platform, with enhanced capabilities in endotoxin ...

ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...